Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain

Vaccine

Volumn 31, Issue 46, 2013, Pages 5486-5494

  Diez Domingo, Javier ^a   Gurtman, Alejandra ^b   Bernaola, Enrique ^c   Gimenez Sanchez, Francisco ^d   Martinon Torres, Federico ^e,f   Pineda Solas, Valentin ^g   Delgado, Alfonso ^h   Infante Marquez, Pilar ⁱ   Liang, John Z ^b   Giardina, Peter C ^b   Gruber, William C ^b   Emini, Emilio A ^b   Scott, Daniel A ^b  

^a Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^b PFIZER INC   (United States)

^c Universidad Pública de Navarra   (Spain)

^d HOSPITAL TORRECÁRDENAS   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f Vaccine Research Unit   (Spain)

^g HOSPITAL DE SABADELL   (Spain)

^h Gynecology and Obstetric Department Torrelodones University Hospital   (Spain)

ⁱ Hospital Virgen del Mar   (Spain)

Author keywords

13 Valent pneumococcal conjugate vaccine; Immunogenicity; Infants; Pneumococcal vaccination; Spain

Indexed keywords

DIPHTHERIA TOXOID CRM197; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; APPETITE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SCREENING; FEMALE; FEVER; GEOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; INJECTION SITE REACTION; IRRITABILITY; LOCAL SKIN REACTION; MALE; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDNESS; SCHOOL CHILD; SERUM BACTERICIDAL ANTIBODY ASSAY; SIDE EFFECT; SLEEP; SPAIN; SWELLING; TENDERNESS; TREATMENT RESPONSE;

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 50% TISSUE CULTURE INFECTIOUS DOSE; 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; ADVERSE EVENT; AE; CI; CONFIDENCE INTERVAL; CRM(197); CROSS-REACTIVE MATERIAL 197 (NONTOXIC MUTANT FORM OF DIPHTHERIA TOXIN); E-DIARY; ELECTRONIC DIARY; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GEOMETRIC MEAN CONCENTRATION; GEOMETRIC MEAN TITER; GMC; GMT; HAEMOPHILUS INFLUENZAE TYPE B; HIB; IGG; IMMUNOGENICITY; IMMUNOGLOBULIN G; INFANTS; INVASIVE PNEUMOCOCCAL DISEASE; IPD; MEASLES, MUMPS, RUBELLA (VACCINE); MENINGOCOCCAL GROUP C; MMR; MNC; MNC CONJUGATE VACCINE USING DIPHTHERIA TOXIN CROSS-REACTIVE MATERIAL 197; MNCCV-CRM(197); PCV13; PCV7; PNEUMOCOCCAL VACCINATION; SAE; SBA; SERIOUS ADVERSE EVENT; SERUM BACTERICIDAL ASSAY; SPAIN; TCID(50);

ANTIBODIES, BACTERIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; SPAIN; VACCINATION;

EID: 84886088423     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.049     Document Type: Article

References (48)

1. Casado-Flores J., Rodrigo C., Arístegui J., Martínón J.M., Fenoll A., Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2008, 27:1020-1022.
2. Centers for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897.
3. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
4. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl. 1):S58-S67.
5. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Active Bacterial Core Surveillance/Emerging Infections Program Network Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
6. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
7. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
8. GSP Summary Report (Stage 1; Version 1) for SAGE meeting November 6-8, 2007; October 18, 2007 version (public document).
9. Black S.B., Cimino C.O., Hansen J., Lewis E., Ray P., Corsaro B., et al. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2006, 25:306-311.
10. Schmitt H.J., Faber J., Lorenz I., Schmöle-Thoma B., Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 2003, 21:3653-3662.
11. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28:4192-4203.
12. ®-IPV+Hib when coadministered with 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers. Poster presented at the Infectious Diseases Society of America (IDSA) 47th Annual Meeting, October 29-November 1 2009.
13. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10:514-519.
14. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997, 4:156-167.
15. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786.
16. Chan I.S.F., Zhang Z. Test based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999, 55:1201-1209.
17. Jódar L., Butler J., Carlone G., Dagan R., Goldblatt D., Käyhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3265-3272.
18. World Health Organization Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series, No. 927 2005.
19. Henriques B., Kalin M., Ortqvist A., Olsson Lijequist B., Almela M., Marrie T.J., et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000, 182:833-839.
20. McIntosh E.D., Fritzell B., Fletcher M.A. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect 2007, 135:644-656.
21. Pérez A., Sala P., Giménez M., Sierra M., Esteve A., Alonso A., et al. Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona. Eur J Clin Microbiol Infect Dis 2004, 23:677-681.
22. Aguiar S.I., Serrano I., Pinto F.R., Melo-Cristino J., Ramirez M., Portuguese Surveillance Group for the Study of Respiratory Pathogens Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008, 14:835-843.
23. Doit C., Mariani-Kurkdjian P., Mahjoub-Messai F., Bidet P., Bonacorsi S., Carol A., et al. Epidemiology of pediatric community-acquired bloodstream infections in a children hospital in Paris, France, 2001 to 2008. Diagn Microbiol Infect Dis 2010, 66:332-335.
24. Dortet L., Ploy M.C., Poyart C., Raymond J. ORP Ile de France Ouest Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 2009, 65:49-57.
25. Guevara M., Barricarte A., Gil-Setas A., García-Irure J.J., Beristain X., Torroba L., et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009, 15:1013-1019.
26. Muñoz-Almagro C., Esteva C., de Sevilla M.F., Selva L., Gene A., Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect 2009, 59:75-82.
27. Salleras L., Domínguez A., Ciruela P., Izquierdo C., Navas E., Torner N., et al. Changes in serotypes causing invasive pneumococcal disease (2005-2007 vs 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin Microbiol Infect 2009, 15:997-1001.
28. Snape M.D., Klinger C.L., Daniels J.T.M., Layton H., Rollinson L., Pestridge S., et al. Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine [abstract]. Poster presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual Meeting, October 25-28 2008.
29. Martinón-Torres F., Gimenez-Sanchez F., Gurtman A., Bernaola E., Diez-Domingo J., Carmona A., et al. 13-Valent pneumococcal conjugate vaccine given with meningococcal C tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J 2012, 31:392-399.
30. Jódar L., Feavers I.M., Salisbury D., Granoff D.M. Development of vaccines against meningococcal disease. Lancet 2002, 359:1499-1508.
31. English M., MacLennan J.M., Bowen-Morris J.M., Deeks J., Boardman M., Brown K., et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2000, 19:1232-1238.
32. Rennels M.B., Edwards K.M., Keyserling H.L., Reisinger K., Blatter M.M., Quataert S.A., et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J 2001, 20:153-159.
33. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179:1569-1572.
34. Buttery J.P., Riddell A., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 2005, 293:1751-1758.
35. Schuchat A., Robinson K., Wenger J.D., Harrison L.H., Farley M., Reingold A.L., et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997, 337:970-976.
36. Knuf M., Szenborn L., Moro M., Petit C., Bermal N., Bernard L., et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009, 28(4 (Suppl.)):S97-S108.
37. Lagos R., Munoz A., Levine M.M., Watson W., Chang I., Paradiso P. Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants. Vaccine 2009, 27:2299-2305.
38. Sigurdardottir S.T., Davidsdottir K., Arason V.A., Jonsdottir O., Laudat F., Gruber W.C., et al. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine 2008, 26:4178-4186.
39. Southern J., Borrow R., Andrews N., Morris R., Waight P., Hudson M., et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009, 16:194-199.
40. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50(2):84-191.
41. Auckland C., Gray S., Borrow R., Andrews N., Goldblatt D., Ramsay M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006, 194:1745-1752.
42. Wysocki J., Tejedor J.C., Grunert D., Konior R., Garcia-Sicilia J., Knuf M., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009, 28(4 (Suppl.)):S77-S88.
43. Wysocki J., Tansey S., Brachet E., Baker S., Gruber W., Giardina P., et al. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines. Vaccine 2010, 28:7779-7786.
44. Esposito S., Tansey S., Thompson A., Razmpour A., Liang J., Jones T.R., et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010, 17:1017-1026.
45. Gadzinowski J., Tansey S., Mellelieu T., Baker S., Giardina P., Gruber W.C., et al. A phase 3 trial evaluating the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine [abstract]. Poster presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual Meeting, October 25-28 2008.
46. Käyhty H., Ahman H., Eriksson K., Sörberg M., Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005, 24:108-114.
47. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsène J.P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(4 (Suppl.)):S66-S76.
48. Public Health England Cumulative weekly number of reports of invasive pneumococcal disease due to any of the seven serotypes in PrevenarTM: children aged <2 years in England and Wales by epidemiological year: July-June (2005- to date) 2008, http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1207821645727.